Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Treasury Shares: 2015-2024

Historic Treasury Shares for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $5.5 million.

  • Intellia Therapeutics' Treasury Shares fell 3.79% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 3.79%. This contributed to the annual value of $5.5 million for FY2024, which is 37.26% up from last year.
  • Per Intellia Therapeutics' latest filing, its Treasury Shares stood at $5.5 million for FY2024, which was up 37.26% from $4.0 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Treasury Shares ranged from a high of $5.5 million in FY2024 and a low of $193,936 during FY2020.
  • Its 3-year average for Treasury Shares is $3.8 million, with a median of $4.0 million in 2023.
  • Data for Intellia Therapeutics' Treasury Shares shows a peak YoY soared of 328.54% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Treasury Shares stood at $193,936 in 2020, then soared by 133.60% to $453,026 in 2021, then soared by 328.54% to $1.9 million in 2022, then spiked by 108.19% to $4.0 million in 2023, then surged by 37.26% to $5.5 million in 2024.